McDonough Randal P, Doucette William R
College of Pharmacy, University of Iowa, Iowa City 52242, USA.
J Am Pharm Assoc (2003). 2003 Jul-Aug;43(4):511-8. doi: 10.1331/154434503322226266.
To determine the number and types of drug therapy problems identified by pharmacists at six community pharmacies, identify the interventions made by these pharmacists in their attempts to resolve drug therapy problems, and determine the results of the pharmacists' actions taken to resolve drug therapy problems.
Retrospective review of patient records from pharmacies.
Six community pharmacies that had participated in Project ImPACT: Hyperlipidemia.
One hundred sixteen patients from Project ImPACT: Hyperlipidemia.
Drug therapy problems, pharmacists' interventions, and results of pharmacists' actions were identified and categorized. Drug therapy problems were classified into seven categories, pharmacists' interventions into six categories, and results were categorized into eight types. Frequencies and descriptive statistics were calculated for the measures.
A total of 512 initial drug therapy problems were reported for 116 patients in the 6 pharmacies. In addition to the initial interventions, pharmacists documented another 545 times in which they intervened on the original problems. There were 354 (69.1%) drug therapy problems associated with hyperlipidemia and 158 (30.9%) with other conditions. Overall, most common types of drug therapy problems were needs additional therapy (39.8%) and nonadherence to therapy (31.1%). The most common discretionary pharmacist interventions were patient education and physician communication, which occurred on average 4.63 and 3.30 times during the project period. The most common consequence of a pharmacist intervention was an increase in patient adherence, which was reported for almost half of the patients.
Drug therapy management (DTM) for patients with dyslipidemias identified frequent drug therapy problems associated with both hyperlipidemia and other conditions. Pharmacists used interventions that included laboratory testing, patient monitoring, patient education, and physician communication to influence patient adherence and optimize drug therapy. Although further research is needed, the findings of this analysis are promising for the more widespread adoption of a DTM role by community pharmacists.
确定六家社区药房的药剂师所识别出的药物治疗问题的数量和类型,识别这些药剂师为解决药物治疗问题而采取的干预措施,并确定药剂师为解决药物治疗问题所采取行动的结果。
对药房患者记录进行回顾性审查。
参与“血脂异常干预项目(Project ImPACT: Hyperlipidemia)”的六家社区药房。
来自“血脂异常干预项目”的116名患者。
识别并分类药物治疗问题、药剂师的干预措施以及药剂师行动的结果。药物治疗问题分为七类,药剂师的干预措施分为六类,结果分为八种类型。计算这些指标的频率和描述性统计量。
六家药房的116名患者共报告了512个初始药物治疗问题。除了初始干预措施外,药剂师还记录了另外545次针对原有问题的干预。有354个(69.1%)药物治疗问题与血脂异常相关,158个(30.9%)与其他病症相关。总体而言,最常见的药物治疗问题类型是需要额外治疗(39.8%)和不依从治疗(31.1%)。药剂师最常见的自主干预措施是患者教育和与医生沟通,在项目期间平均分别发生4.63次和3.30次。药剂师干预最常见的结果是患者依从性提高,几乎一半的患者报告了这一情况。
血脂异常患者的药物治疗管理(DTM)发现了与血脂异常和其他病症相关的常见药物治疗问题。药剂师采用了包括实验室检测、患者监测、患者教育和与医生沟通等干预措施来影响患者依从性并优化药物治疗。尽管需要进一步研究,但该分析结果有望促使社区药剂师更广泛地发挥药物治疗管理的作用。